HLBI/5FU combination effect for colo-rectal carcinoma as adjuvant chemotherapy
作者单位：Department of Surgery The Jikei University School of MedicineTokyo JAPAN Department of Surgery The Jikei University School of MedicineTokyo JAPAN Department of Surgery The Jikei University School of MedicineTokyo JAPAN Department of Surgery The Jikei University School of MedicineTokyo JAPAN Department of Surgery The Jikei University School of MedicineTokyo JAPAN
会议名称：《第六次全国大肠癌会议暨中日韩大肠癌会议》
会议日期：1998年
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
摘 要：正HLBI/5FU combination chemotherapy was used for the treatment of unresectable or recurrent colo-rectal carcinoma. The response rate of this combination treatment was 43％. Therefore, HLBI/5FU combination chemotherapy was tried as adjuvant chemotherapy for the patient with Dukes C colo-rectal carcinoma who had curative resection.